Testing a biosimilar of Phesgo® in healthy men
This trial tests a new version of a cancer drug (called HLX319) to see how it compares to the approved drug Phesgo®. It is for healthy male volunteers to check how the drug behaves in the body, its safety, and any immune reactions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man between the ages of 18 and 45.
- You need to weigh between 110 and 165 pounds, with a body mass index (BMI) between 19 and 24.
- You should be in good health — no ongoing medical issues like heart, liver, or kidney problems.
- Your heart function, as measured by an ultrasound, must be normal (ejection fraction of 55% or higher).
- You cannot have taken any prescription or over-the-counter drugs (including supplements) in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the body handles a medication called HLX29 compared to a similar one called HLX11 in healthy men. It helps find the right dose and check for side effects.
This trial tests a new drug called SNH-119014 for the first time in humans. It involves healthy volunteers to check the drug's safety and how the body processes it. It may be a step toward a new treatment for certain conditions.
This study tests whether a new drug called HLX319 works as well as the standard combination drug Phesgo in treating HER2-positive breast cancer before surgery. Both drugs target specific proteins on cancer cells to help shrink tumors and improve outcomes.
This is an early-stage safety test of a new investigational drug called HSK56630 in healthy volunteers with no major medical conditions. Researchers will monitor how your body tolerates the drug and what side effects might occur.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
This trial tests a new daily pill called HLX97 for people with advanced cancers that have stopped responding to standard treatments. It may help if you have a type of breast cancer that is hormone-receptor positive and HER2-negative, or castration-resistant prostate cancer, or non-small cell lung cancer.
Hear when a new Health Adult Subjects trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.